Given that PRKCQ amplification has been observed in 20%–30% of CTCL patients,52,53 it is unlikely that this somatic mutation alone is sufficient to potentiate neoplastic T cell activation. The gene discussed is PRKCQ; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.